Glaukos Corporation reported significant financial developments in its 2025 fiscal year, with net sales reaching $507.4 million, a 32% increase from $383.5 million in 2024. This growth was primarily driven by a 50% rise in U.S. glaucoma product sales, totaling $298.6 million, largely attributed to the successful launch of the iDose TR product. However, the company also faced challenges, including a substantial increase in cost of sales, which rose 139% to $224.7 million, largely due to a $112.9 million impairment charge related to its Photrexa developed technology intangible asset. As a result, Glaukos reported a net loss of $187.7 million for the year, compared to a loss of $146.4 million in 2024.
In terms of strategic developments, Glaukos made notable advancements in its product offerings. The company received FDA approval for Epioxa, a new treatment for keratoconus, in October 2025, and plans to begin commercialization in early 2026. Additionally, Glaukos acquired Mobius Therapeutics for $12.4 million, which includes the FDA-approved Mitosol product, further expanding its portfolio in the glaucoma treatment market. The company also achieved EU Medical Device Regulation certification for its iStent family of products, allowing for initial commercial launch activities in key European markets.
Operationally, Glaukos reported a total employee headcount of 1,094 as of December 31, 2025, reflecting its ongoing investment in expanding its workforce to support growth. The company’s international sales of glaucoma products also increased by approximately 18%, indicating a positive trend in global market penetration. However, Glaukos faced challenges related to supply chain disruptions and inflationary pressures, which have impacted its gross margins and operational efficiency.
Looking ahead, Glaukos anticipates continued growth driven by the commercialization of iDose TR and Epioxa, alongside efforts to streamline reimbursement processes for its products. The company is actively working with Medicare Administrative Contractors to establish consistent reimbursement for iDose TR, which is expected to enhance its market adoption. Despite the challenges posed by fluctuating reimbursement rates and competitive pressures, Glaukos remains focused on expanding its product offerings and improving patient outcomes in the ophthalmic sector.
About GLAUKOS Corp
Glaukos is an ophthalmic pharmaceutical and medical device company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases. Its core products include Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release pharmaceuticals, and bio-activated therapies. Serving global markets, the company focuses on improving clinical outcomes through proprietary technologies, extensive R&D, and regulatory expertise in ophthalmology. Its business model emphasizes product development, commercialization, and strategic licensing.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.